

JCWSCS 2 0 JAN 2004

01-19-2004 02:33pm From-

T-746 P.001/004 F-636

PTO/SB/21 (08-03)

Approved for use through 08/30/2003. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)	Application Number	10/669,990	
	Filing Date	September 24, 2003	
	First Named Inventor	Hector F. DeLuca	
	Art Unit	3661	
	Examiner Name		
Total Number of Pages in This Submission	4	Attorney Docket Number	1256-00819

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Receipt Postcard Request for Corrected Filing Receipt
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Thomas M. Wozny, Reg. No. 28,922 Andrus, Sceales, Starke & Sawall, LLP
Signature	<i>Thomas M. Wozny</i>
Date	January 19, 2004

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.	
Typed or printed name	Dorothy A. Hauser
Signature	<i>Dorothy A. Hauser</i>
Date	January 19, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

## PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No. :	10/669,990	)	CERTIFICATE OF FACSIMILE
Applicant :	Hector F. DeLuca et al	)	TRANSMISSION
Filed :	September 24, 2003	)	I hereby certify that this correspondence is
Title :	Use of 2-Methylene-19-Nor-	)	being facsimile transmitted to: Office of
	20(S)-1 $\alpha$ ,25-	)	Initial Patent Examination's Filing Receipt
	Dihydroxyvitamin D <sub>3</sub> to	)	Corrections, Commissioner of Patents,
	Increase the Life Expectancy	)	P.O. Box 1450, Alexandria, VA 22313-
	of Human Beings	)	1450, on this 19th day of January, 2004.
		)	Facsimile No. 703-746-9195.
TC/A.U. :	3661	)	
Examiner :		)	<i>Dorothy A. Hauser</i> January 19, 2004
Docket No. :	1256-00819	)	Dorothy A. Hauser Date

REQUEST FOR CORRECTED FILING RECEIPT

Facsimile Transmitted to: 703-746-9195

Office of Initial Patent Examination's

Filing Receipt Corrections

Commissioner for Patents

Washington, D.C. 20231


Sir:

1. Attached to this Request is a copy of the Official Filing Receipt received from the PTO in the above application.
  2. There are errors in the "Title" of the Filing Receipt. The correct title is as follows:  
"Use of 2-Methylene-19-Nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> to Increase the Life Expectancy of Human Beings"
  3. The errors are circled on the attached copy of the Filing Receipt. The words "Use of" are to be added to the beginning of the title and "1 $\alpha$ " should be either "1Alpha" or "1 $\alpha$ ".
  4. These errors are not due to any mistake by Applicant and no fee is due.
- Therefore, it respectfully requested that a Corrected Filing Receipt be issued correcting the title of the above-identified patent application.

Respectfully submitted,

ANDRUS, SCEALES, STARKE &amp; SAWALL, LLP

By

  
 Thomas M. Wozny  
 Reg. No. 28,922

Andrus, Sceales, Starke & Sawall, LLP  
 100 East Wisconsin Avenue, Suite 1100  
 Milwaukee, WI 53202  
 (414) 271-7590



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/669,990	09/24/2003	3661	393	1256-00819		22	3

CONFIRMATION NO. 4223

26753

ANDRUS, SCEALES, STARKE & SAWALL, LLP  
 100 EAST WISCONSIN AVENUE, SUITE 1100  
 MILWAUKEE, WI 53202

## FILING RECEIPT

\*OC000000011503395\*

Date Mailed: 12/16/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Hector F. DeLuca, Deerfield, WI;  
 Lori A. Plum, Madison, WI;  
 Margaret Clagette-Dame, Deerfield, WI;

Domestic Priority data as claimed by applicant

Foreign Applications

If Required, Foreign Filing License Granted: 12/15/2003

Projected Publication Date: 03/24/2005

Non-Publication Request: No

Early Publication Request: No

\*\* SMALL ENTITY \*\*

Title

Use of

Alpha

2-Methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D3 to increase the life expectancy of human beings

Preliminary Class  
701

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Contr l, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).